A great story here:
For Dr. Lisa Newman, a 16-hour trip over two days from Michigan to Ghana in Africa is just part of the journey in uncovering clues about a rare form of breast cancer.
Dr. Lisa Newman hopes to uncover clues in Ghana about an aggressive and rare form of breast cancer.
Newman, a surgical oncologist specializing in breast cancer at the University of Michigan, collaborates with doctors in Kumasi, Ghana, in hopes of discovering the origins of an aggressive and difficult to treat form of breast cancer that disproportionately affects black women. It is called triple negative breast cancer or TNBC.
"The women that are most likely to be afflicted with the triple negative breast cancers are younger aged women, women in the pre-menopausal age range, and women with African ancestry," says Newman.
Read the entire story here.
Hope and help for triple-negative (TNBC) and other forms of hormone-negative breast cancer.
Tuesday, July 21, 2009
Dr. Heads to Ghana to Study Triple Negative
Friday, July 17, 2009
New clinical trial scheduled for BSI-201 for triple negative
Monday, July 13, 2009
African Americans Get Different Form of Cancer, Study Says
A study on racial disparities in breast cancer published in the Journal of the National Cancer Institute challenges the assumption that receptor status is the primary reason African-Americans have more agressive forms of breast cancer.
Researchers discovered that black patients with breast cancer had worse survival than white patients, despite identical treatment and follow-up and irrespective of hormone receptor status. They say this shows that African-American women may get a different type of cancer altogether--something that cannot be entirely explained as hormone-receptor negative or triple-negative. And this cancer is highly aggressive. The research also casts doubt on the theory that lower survival rates among African-Americans for certain cancers are due solely to factors such as poverty and poor access to quality health care.
The study used data from the National Cancer Institute’s Surveillance, Epidemiology, and End Results (SEER) program on 244,786 women diagnosed from January 1990 through December 2003 and followed through December 2004.
According to an article from the National Institutes of Health, researchers found that:
...regardless of ER status, black women with breast cancer were still more likely to die of the disease than white women. This disparity remained even when the researchers adjusted for age at diagnosis, stage and grade of the tumor, year of diagnosis, and socioeconomic status. When the researchers examined the hazard rate trends in black and white women, they noticed that the largest differences occurred in the first three years after diagnosis in both ER- and ER+ tumors.
Why do blacks have more aggresive tumors, even allowing for receptor status? Researchers suggest the environment and genetics may both be an issue. The NIH added:
This analysis confirmed that, despite the higher incidence of ER- tumors (which are associated with a less favorable prognosis) among black women, the differences in survival outcomes between the two populations were driven largely by differences in the hazard rate as opposed to differences in estrogen-receptor status.
Sunday, July 12, 2009
EZH2 Protein Being Studied for Effect on Triple Negative
Rochester NY: Discussion on Triple-Negative
Dr. Zachary Kramer of the Lipson Cancer Center will speak.
Admission is free. Call (585) 473-8177 for more information.
Saturday, July 11, 2009
Women with Hormone-Negative Breast Cancer Face Triple the Risk of Cancer in the Second Breast
P53 Mutation Most Common in Women with Hormone-Negative Breast Cancer
Researchers say that nearly 26 percent of women with breast cancer have a mutation in the p53 gene, which repairs damage to the DNA. And it’s most prevalent among premenopausal women with ER-/PR- breast cancer and in postmenopausal hormone-negative women with a high body mass index (BMI). The latter group had higher-grade tumors and a poorer outcome. High BMI is already considered a risk factor for breast cancer.
The study included 1,170 women diagnosed with breast cancer between 1996 and 2001 and 2,116 women without cancer, and was designed to look at how lifestyle and environmental factors affect breast cancer.
"The p53 gene is the guardian of the genome because it signals the cell to repair DNA damage when that occurs. If we can find genetic or environmental risk factors that lead to damage of p53 or stress on the gene, we may be able to help prevent development of breast cancer as well as other cancers," says the study's lead investigator, Catalin Marian, MD, PhD, a research instructor of cancer genetics and epidemiology at the Lombardi Comprehensive Cancer Center at Georgetown University Medical Center (GUMC)The research was presented at the 2009 annual meeting of the American Association for Cancer Research. Read more here.
New Gene May Provide Key to Basal Breast Cancer
Many triple-negative breast cancer tumors are basal, and these are the most aggressive. Researchers have isolated a gene—the Met gene—that is in the majority of breast cancers. More aggressive forms of cancer—basal types—have more of the gene. There are existing inhibitors for this gene, so scientists say this study may lead to new treatment for triple negative and other hormone negative forms. Researchers were associated with the Van Andel Research Institute in Grand Rapids, Michigan, headed by George Vande Woude, Ph.D., who has been studying the Met gene since the 1980s.
"This very exciting work by the Van Andel Research Institute gives us a new target for treatment of patients with one of the worst types of breast cancer — basal breast cancer," said Dr. Daniel D. Von Hoff, Physician-in Chief of the Translational Genomic Research Institute (TGen) in Phoenix, Arizona, which initiated an alliance with Van Andel Institute in February. "Since there are many new inhibitors of Met available for clinical trials, we now have a direct route for immediate application of these important findings in the care of patients with this very aggressive form of breast cancer."
Read more here.
Tuesday, July 7, 2009
Vitamin A May Lead to Drug for Triple Negative
Retinoic acid, a component of Vitamin A, has the potential to treat breast cancer, including triple negative, according to research in the June 24, 2009 issue of the journal Cell.
The main story being reported is on retinoic acid’s influence on hormone-positive breast cancer, helping the body balance the effect of hormones. Here’s how it goes: estrogen makes cells grow rapidly; retinoic acid slows that process down. And that's an important story.
But researchers say retinoic acid can even help cancers that are not fueled by estrogen—that is, hormone-negative cancers such as triple negative. And that's a bigger story, because at this point triple negative breast cancer has no drug therapy, as the primary breast cancer drugs, tamoxifen and Arimidex, are designed to combat estrogen, which is not a factor in estrogen-negative cancer.
From a news release from the University of Chicago, whose scientists conducted the research:
"Understanding all the components of this process could be used against breast cancer care in three ways," said study leader, Kevin White, PhD, professor of human genetics and director of the Institute for Genomics and System Biology at the University of Chicago. "It suggests new ways to think about preventing the disease in those at high risk. It offers molecular tools that could provide a more precise diagnosis and predict outcomes. It could also be used to enhance current therapies, making existing drugs, such as tamoxifen, that selectively block estrogen's effects even more powerful, or even to develop new anti-cancer drugs."
White's team studies the effects of nuclear receptors, a class of proteins found within cells that control the response to various hormones. When a hormone enters a cell and connects with its receptor, that receptor alters the pattern of expression of specific genes--often hundreds or more.
But, they note, cancers that do not respond to hormones can also be affected.
This competition between the two signals also provides a new tool to predict outcomes. The researchers compared the effects of retinoic acid on tissues from 295 breast cancer patients against the results from their initial study using a typical breast cancer cell line. They found that the more responsive a tumor was to retinoic acid, the better the odds of long-term relapse-free survival.
Some of the genes that respond to retinoic acid were expressed even in difficult-to-treat tumors, such as those that do not have estrogen receptors or the molecule targeted by the drug Herceptin, the so-called double- or triple-negative breast cancers. "Some of these genes may provide new drug targets," White said.
Although retinoic acid is approved for treatment of leukemia, it can be quite toxic and patients can develop resistance to the drug. This study suggests a long series of downstream targets that are activated by the RA receptor.
"The goal would be to develop drugs that could activate these cancer-inhibiting targets," said White. “Retinoic acid itself is probably not the solution because of its side effects and metabolic byproducts," He cautioned, "but our results provide a molecular justification for finding ways to overcome its limitations in the clinic.”
Wednesday, June 24, 2009
PARP Inhibitors May Help More Than Triple Negative
I’ve written about PARP inhibitors recently, but they’re back in the news.
Patients with cancer genes—BRCA1 and BRCA2—have been shown to react positively to a type of PARP inhibitor, a drug called olaparib. In a small but significant study, olaparib was successful in shrinking breast and prostate cancer tumors, with some disappearing entirely. The study was reported in the New England Journal of Medicine.
Read more about it here.
PARP is short for poly (ADP-ribose) polymerase, an enzyme used by cancer cells to repair DNA damage.
Friday, June 19, 2009
Herceptin May Be Effective Drug for Hormone Negative Breast Cancer
The drug commonly used for Her2-positive breast cancers may actually turn ER-negative status into positive. It’s a two-step process, though, and the research was done on ER-negative, Her2-positive laboratory cells, not on human subjects. Still, it offers amazing potential and could ultimately provide much-needed therapy for hormone-negative breast cancer, including triple negative.
After being treated with trastuzumab (Herceptin), ER-negative cells actually turned into ER-positive cells, making them then react to anti-estrogen drugs like tamoxifen and aromatase inhibitors, according to research presented at the Endocrine Society meeting this month.
The research was done in vitro—in a lab, on existing cells, rather than in human subjects. Cells were ER-negative, Her2-postive and were treated with trastuzumab; after 72 hours they were treated with the hormones estradiol and androstenedione. After that they were given aromatase inhibitors and antiestrogens.
The tumors then reacted in much the way ER-positive tumors do to aromatase inhibitors and antiestrogens.
Read more about the study here.
SOURCE: Sabnis G, Brodie A "Trastuzumab sensitizes ER negative, HER-2 positive breast cancer cells (SKBr-3) to endocrine therapy" ENDO 2009; Abstract OR38-02.
Monday, June 15, 2009
Oral Contraceptives Increase the Risk of Triple Negative Breast Cancer
Women under the age of 40 who used oral contraceptives increase their risk of triple-negative breast cancer by more than 2.5 times, according to research in Cancer Epidemiology Biomarkers and Prevention (April, 2009). There was no increase in the risk for hormone-positive breast cancer.
Sunday, June 14, 2009
Scientists study protein linked to triple negative
Researchers speculate that EZH2 could ultimately be much-needed therapy for women with hormone-negative breast cancer. The study is continuing with the goal of determining EZH2's role in survival of hormone-negative cancer.
Tuesday, June 9, 2009
More perspective on PARP inhibitors for triple negative
An expansion on my previous post on PARP inhibitors:
A Curetoday.com blog gives a bit more explanation on the recent research (presented at the American Society of Clinical Oncology annual meeting) showing how PARP inhibitors can help advanced triple negative breast cancers:
What happens when a preliminary study that was not designed for drug approval ends up showing dramatic results?
A study in patients with advanced "triple negative" breast cancer (defined as being negative for estrogen, progesterone, and HER2 receptors) compared chemotherapy (Gemzar and carboplatin) with or without BSI-201, a poly ADP-ribose polymerase (PARP) inhibitor.
PARP inhibitors have been shown to work exceptionally well in the laboratory against cancers that have defects in DNA repair – this is an abnormality that is prominent in cancers that derive from patients who have inherited mutations in the breast and ovarian cancer predisposing genes BRCA1 and 2. It turns out that BRCA1-associated tumors tend to be triple negative (although not all triple negative tumors have abnormalities of the BRCA pathways).
This was a preliminary phase II study, so even though it was randomized, it did not have enough patients to qualify as an FDA-approval trial. But it nevertheless showed unprecedented effects on inducing tumor responses, delaying time to progression, and improving survival – even greater than hormonal therapy and Herceptin have.
Read the entire article here.
Sunday, June 7, 2009
Two stories of women coping with triple negative
“We’re a package deal.”
That’s how Heather Gideon describes her relationship with Angie Huxtable.
So when Huxtable agreed to be in today’s style show for the annual Cattlemen’s Ball of Nebraska, Gideon said, there was absolutely no question she would appear on the runway as well.
The style show is just one of the many activities that will help raise money for cancer research as part of the 2009Cattlemen’s Ball, which has a goal of collecting $1 million.Whatever amount is raised will go to the UNMC Eppley Cancer Center and local health care organizations.
That money for research is important to both Wood River women, who were each diagnosed with breast cancer in May 2007.
While Huxtable remains cancer free, Gideon’s cancer re-emerged just months after her initial round of treatment was finished. Gideon is now diagnosed with Stage 4 breast cancer.
“I’ve been given one to four years to live,” said Gideon, who noted there is no current treatment that doctors say will cure her cancer.
Treatments now are designed to hold the cancer at bay.
Another Triple Negative Survivor Story
Hope and healing are often found in the unlikeliest of places. Breast cancer survivor Candy Reid found source of hope in a circle of tubing better known as the hula hoop.
Reid is the founder of Hoops for Healing, a online business that sell hula hoops custom made by Reid and her family.She said that she cannot believe how the business has taken off and that the journey from battling cancer to operating a successful business was as circular as the hoops she now makes from her home in Albany.
"What came from this horrible experience is amazing to me," said Reid. "I've grown a lot, I've changed a lot. God has really been able to show his goodness through so many ways."
She said that before hearing the terrible news that she had breast cancer in December 2007, she was a busy housewife dedicated to home schooling her four children.
"I am really dedicated to my family and they have been so supportive through all this," Reid said.
She said that she was diagnosed with triple negative breast cancer, a specific subtype of cancer that is clinically characterized as more aggressive and less responsive to standard cancer treatments.
"I immediately began chemotherapy treatments which ended in May 2008 and then I had a bilateral mastectomy in June 2008," Reid explained. "This was followed by seven weeks of radiation."
Saturday, June 6, 2009
Your Nurse Can be Your Advocate
In the confusing days and weeks after a breast cancer diagnosis, a nurse navigator or patient advocate can help you make sense of your disease and its treatment and even guide you in getting a second option. Nurse navigators follow cancer patients from diagnosis through follow-up care and help make sense of the doctors, treatments, jargon, and options while providing a supportive presence. In most cases, navigators collaborate with all members of the medical team; educate and counsel patients and their families; and coordinate care with oncologists, surgeons, pharmacists, dieticians, and counselors.
Check to see if your healthcare provider offers access to such a professional. If not, lobby for them to start. We all need more information than we have after a breast cancer diagnosis. We should not be left to our own devices to figure it all out.
Cancer-Fighters in Your Kitchen
• Whole grain breads and cereals fortified with B vitamins, especially folate. Folate is important in fighting hormone-negative breast cancer.
• Cruciferous vegetables: broccoli, cauliflower, cabbage, kale. These are high in Indole-3-Carbonale (I3C) that has been shown to have anti-cancer properties.
• Fruits and vegetables, especially brightly colored. Red and purple plants—red cherries, blueberries, acai—are high in anthocyanins, which are potent antioxidants.
• Green tea, which contains plant chemicals called catechins, a plant chemical that may inhibit the invading capacity of breast cancer cells.
• Flaxseeds, which contain cancer-fighting lignans.
• Organic foods when possible, especially dairy products. Organic food is grown or produced without the use of pesticides, fertilizers, antibiotics or growth hormones, all of which are implicated in breast cancer.
It’s Not a One-Size-Fits-All Disease: Breast Cancer Myths
MYTH 1: Breast cancer is always fatal. fact: The great majority of women with breast cancer go on to live long and meaningful lives. Ninety-three percent of the women with the most common type, hormone-positive, are disease-free at five years.
MYTH 2: There’s always a tumor. FACT: two types—lobular and inflammatory—may have no lumps. Women with lobular often have thickening of the breasts; those with inflammatory usually have red, swollen breasts, often with a pitted appearance.
MYTH 3: Estrogen is always the culprit. FACT: there’s a form of breast cancer that most often strikes young women, that is not fueled by estrogen.
MYTH 4: Tamoxifen or Arimidex are for everybody. FACT: women with estrogen-negative disease get no benefit from these drugs, which are estrogen blockers. This is especially important, as these drugs have significant side effects, one of which is an increased risk of other cancers.
A Weight-Loss Strategy That Works: Your Friends
• Make a formal diet and exercise plan and publicize it. Going public makes it harder to fall off the wagon.
• Don’t diet—change the way you eat. This is not a short-term goal, but a long-term change. And your family will benefit from a healthier diet as well—you will be helping them reduce their cancer risk.
• Have healthy potlucks. Show off your low-calorie, low-fat, low-cholesterol recipes and show one another that you can still enjoy food together.
• Pool your money to hire a dietician. Most cancer clinics have access to these professionals.
• Have fun—get a dance video game, round up the kids and boogie the pounds away.